J Ayurveda Integr Med 5(4):241 Genere N, Stan MN (2019) Current and emerging treatment strategies for Graves orbitopathy
Antioxidants in health, disease and aging
The key regulatory milestones: FDA Breakthrough Therapy designation for MASH (September 2024) EMA PRIME designation for MASH (November 2023) China NMPA Breakthrough designation (June 2024) Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) fully enrolled, results expected H1 of this year Estimated FDA filing: Late this year at the earliest Estimated FDA approval: Possibly next year, depending on Phase 3 results If Phase 3 results confirm Phase 2 findings, survodutide could reach the market within the next 12-24 months
This FAQ section highlights the most common topics, offering clear guidance on safety, scheduling, benefits and how these injections may complement other nutrient based services
For the most consistent, reproducible scientific results, plan your research timeline around a 14-day window per vial
Horrigan, 2006